News | February 13, 2021
Steady performance; for Alkem Laboratories: ICICI Securities
The company continued to maintain clear FDA status across its plants and has received 12 ANDA approvals during 9MFY21
The company continued to maintain clear FDA status across its plants and has received 12 ANDA approvals during 9MFY21
Veteran quality professional with over 20 years of industry experience to lead quality operations at Unit-4 API manufacturing facility
Seasoned pharma leader recognized for driving sales excellence, marketing strategy, and business growth
DCGI-approved semaglutide syringes for diabetes and obesity expand treatment choices and improve affordability
Strong domestic and international growth, improving product mix, and operational efficiencies drive margin expansion despite exceptional charges impacting quarterly profit
The event is expected to attract more than 100 senior professionals from pharmaceutical companies, CROs, regulatory agencies, and technology organisations
Mumbai event on June 24–25 will spotlight real-world impact of pharmacovigilance beyond AI adoption
New adult supplement combines 26 vitamins, minerals and botanicals to address stress, energy, immunity and cognitive wellness in one daily tablet
As demand for GLP-1 therapies explodes, India’s drug regulator moves to curb advertising amid rising concerns over misuse, access, and long-term impact
The Pre-Approval Inspection (PAI) was completed on February 13, 2026, and the company is initiating corrective actions.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
